A systematic review of cost projections of new vaccine introduction from researchers at Levin & Morgan and WHO has just been published in Vaccine. This review aimed to address gaps in the current guidance on cost projections for new vaccine introduction on methods of sampling, data collection and analysis. See the highlighted findings below and read the full article.
The majority of new vaccine cost projections have been conducted in high- and middle-income countries.
Most cost projections were part of a cost-effectiveness or cost-benefit analysis to assist decision-making on introducing a new vaccine.
Over half of the studies utilized secondary cost data, indicating the importance of improving accuracy of vaccine cost projection estimates.
Around half of studies underestimated delivery costs of introducing new vaccines since these left out introduction and operational costs.
Any organization or individual working in the field of immunization economics can submit findings, opportunities, calls to action, or other relevant work below to be shared with our community.